ImmuCell Corporation Inc (ICCC) - Price-to-Projected Revenue Ratio

The forward P/S multiple illustrates the market valuation dynamics of ImmuCell Corporation (ICCC), with the value of 3.00 serving as the current metric. Business revenues are based on the sale of First Defense biologicals for calf protection. The environmental contribution consists of reducing antibiotic use in livestock farming. Operational stability is ensured by diversified raw material procurement and streamlined logistics within the US.

ImmuCell - ICCC Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/14/2026)

ICCC (ImmuCell Corporation Inc): analytical breakdowns and indicator data

- stock price and consensus target price:

Stock Quotes ImmuCell|ICCC - Fair Value Consensus

- market capitalization indicators:

Market Value ImmuCell Corporation Inc|ICCC - Value Adjusted for Debt and Cash

- book value of equity indicators:

Book Value per Share ImmuCell|ICCC - Total Stockholders' Equity|Market Value to Book Value Ratio immucell.com|ICCC - Company Total Asset Base

- debt and solvency information:

- financial results and valuation multiples details:

ICCC - Company Net Income|Expected Profit ImmuCell Corporation|ICCC - Business Payback Period|Forward P/E Multiple ImmuCell Corp.|ICCC - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmuCell Corporation Inc|ICCC - Operating profit before deduction of amortization|Earnings per share for the last twelve months ImmuCell|ICCC - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months immucell.com|ICCC - Earnings growth in current year|Earnings growth forecast for next year ImmuCell Corporation

- revenue and sales details:

ICCC - Company Sales|Projected Sales Volume ImmuCell|ICCC - Price to Sales|Price-to-Projected Revenue Ratio ImmuCell Corporation Inc

Fundamental company analysis:ICCC (ImmuCell)

The forward P/S is calculated as the quotient of the current market capitalization to the expected annual sales volume, measuring the premium the market is willing to pay per unit of future revenue. For ImmuCell Corporation (ICCC), this forward price-to-sales ratio reflects market expectations regarding the scaling of First Defense antibody production and the expansion of manufacturing capacities within the agricultural sector.

Key competitors

Corteva - Forward Price-to-Revenue Multiple|Forward Price to Sales NTR|CF - Price-to-Projected Revenue Ratio|Forward Price to Sales MOS (Mosaic Co.)|ELAN: Forward P/S Multiple|Market Cap to Future Revenue Ratio balchem.com (BCPC)|Price-to-Projected Revenue Ratio FMC Corp.|Miracle-Gro (SMG) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Phibro (PAHC)|UAN - Market Cap to Future Revenue Ratio|Oil-Dri Corporation - Forward Price-to-Revenue Multiple|Forward P/S Multiple intrepidpotash.com IPI|LVRO - Price-to-Projected Revenue Ratio|Forward Price to Sales AVD (American Vanguard)|GRO: Forward P/S Multiple|Forward Price-to-Revenue Multiple Enlightify Corporation|SEED (Origin Agritech Ltd.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cgagri.com CGA|Price-to-Projected Revenue Ratio S&W Seed Co. (SANW)